The founder of CHA University and the Chairman of the CHA
The world looks closely at the success of Dr. Cha's medical venture
The success story of CHA General Hospital crosses the ocean and goes on in the U.S.
Dr. Cha Kwang Yul is an internationally celebrated scientist in infertility and reproductive medicine and a successful businessman who founded a number of medical and educational institutions including the CHA Medical Centers in Gangnam, Bundang, and Gumi; Daegu CHA Women's Hospital; and CHA University. In 1999 Dr. Cha established New York C.C. Infertility Center with the Columbia University.
- Following the opening of C.C. Infertility Center in New York, Dr. Cha opened the L.A. Infertility Center, and in November 2004, he acquired Los Angeles Hollywood Presbyterian Medical Center, which was recorded as the first acquisition of a U.S. general hospital by a Korean. The acquisition proved that he not only is a medical talent, but also has keen eye for strategic business. His entrepreneurial brilliance and the insight for business have become an envy for many.
- Dr. Cha's Stem Cell Institute pushes the boundaries of human life.
Dr. Cha spares no effort or expense in stem cell research. In 2000, he founded a
company called CHA Bio & Diostech for the development of cellular therapies using
the stem cells; and in 2006 he built Korea's largest stem cell clinic and research
center with the state-of-the-art research facilities. Today, he is concentrating
on building an integrated stem cell bank, to treat the diseases that are incurable
today, such as adult leukemia, diabetes, incontinence, stroke, brain hemorrhage,
musculoskeletal disorders, and cardiovascular diseases.
Dr. Cha plans to erect a super-scale medi-cluster near Bundang CHA General Hospital to integrate an international stem cell treatment center, an international stem cell clinical research center, an industry-university cooperation center, an education institute and more, and seek close collaboration with Bundang CHA General Hospital, to maximize the synergy effect for basic and clinical medical researches.
Furthermore, CHA Medical Group plans to build the CHA Medical Group Integrated Stem Cell Institute in Pan'gyo Techno-Valley south of Seoul; and with the manufacturing plant soon to be built to supply the artificial blood currently in development by CHA Bio & Diostech and ACT(Advanced Cell Technology) of Austin, Texas, the Group will have the capability to study the patients, secure the blood, and treat them all in one place. This $100 million megalopolis of medical research center will truly be world class, and house a stem cell research center, an ovum bank, a sterile, GMP-qualified fertilization facility to manufacture medicines, a cord blood bank, an immune and vaccine research institute, an artificial internal organ lab; as well as professional development and training facilities including a school of biosciences and a medical school.
- CHA Medical Group brings tomorrow's biotechnology to today's biotech industry.
- Based on the unique, exceptional infrastructure built in the CHA Medical Group, Dr. Cha founded CHA Bio & Diostech and created the system to fulfill the most basic needs of patients to the capability to solve the most complicated clinical cases. CHA Bio & Diostech is leading the world biotechnology industry and has grown fast to become a world renowned medical venture with the solutions for the treatment of many different hematological cancers once regarded uncurable, and with the key technology which allows for the proliferation of human embryonic stem cells. In December 2008, CHA Bio & Diostech and Advanced Cell Technology of Austin, Texas, the name that represents the stem cell research in the U.S., have formed a joint venture company Stem Cell & Regenerative Medicine International (SCRMI) to research, manufacture, and commercialize the artificial blood. Currently, SCRMI is at about 70% in the development of artificial blood technology, and the development will be over 95% complete in just few years, which is when CHA Bio & Diostech will have built a production system for SCRMI to supply artificial blood globally. A true visionary and a pioneer, Dr. Cha is raising the status of Korean medical technology to a higher level.
- Internationally acclaimed authority on infertility and reproductive medicine.
- Dr. Cha offers new hope to infertile couples.
- Dr. Cha was a well known ob/gyn specialist before he raised the level of Korean infertility technology to the global level. After he became a licensed obstetrician, he worked at Yonsei Severance Hospital for a year as an intern, and then he went to the University of Southern California to study Reproductive Endocrinology and Infertility, the field explored only by few back then. While studying the subject Dr. Cha predicted that the infertility treatment was the future, and that this branch of reproductive medicine would be in big demand. It was only natural when he returned to Korea Dr. Cha established CHA Fertility Center, the first reproductive medicine research institute in Korea. As a result in 1986 the first Korean test-tube baby was born in a CHA Fertility Center facility, and this success has become a catalyst for the growth of reproductive medicine research in Korea. Dr. Cha was also successful in achieving pregnancy and bringing the baby to the world with an immature ovum; and recently at CHA Fertility Center a healthy baby was born from a vitrification-stored egg for the first time in world medical history.
- Dr. Cha's papers on the subject of infertility and reproductive medicine are the textbooks for today's scientists.
Dr. Cha's papers including The Fertility and Sterility published in 1991 and The Human
Reproduction Update published in 1998 are conceived today as the representative research
papers in the subject of infertility and reproductive medicine. Quoted more than a hundred
times to date, his papers are treated as the textbooks for the scientists who study the
subject. By expanding the clinical application of his findings, he has achieved 28% pregnancy
rate from the patients of polycystic ovary syndrome.
In 1998, his team of researchers announced breakthrough in the embryo cryopreservation
arena. Termed vitrification, it involves freezing the embryo about 600 times faster than before
this ultrarapid process is so fast that it literally allows no time for intracellular
ice to form. As a result,
vitrification avoids trauma to the embryos. In conventional freezing, 20 to 30% of embryos do not
survive the freeze-thaw, and those that do survive have less than half the likelihood of generating a pregnancy as do fresh embryos. In contrast, vitrified embryos have a better than 95% free-thaw survival rate, and a pregnancy generating potential that is comparable to fresh embryos. This finding was given the honor of Best Paper Awards in both the 16th World Fertility Society Conference and in the 54th ASRM Conference. Two of the reproductive medicine textbooks, Textbook of Assisted Reproductive Technique and Vitrification in Assisted Reproduction contain the chapter "Vitrification of oocytes using gold grind and slush nitrogen," and a German textbook Die Endoskopischen Operation in der Gynakologie Refertilization includes the superior technique of endoscopic surgery used by CHA physicians.
- Research findings by Dr. Cha and his scientists make the headlines on internationally recognized periodicals.
- Research findings by Dr. Cha and his scientists make the headlines on the well-recognized periodicals including Time, Newsweek, and People. Dr. Cha has been invited to speak in more than 100 international symposium, educating his findings and experience to the colleagues. His academic achievements include about 80 internationally published research papers and over 200 papers published locally.
- Dr. Cha receives the Best Paper Award six times and leads the reproductive medicine field.
In 1989, he collected the immature ova residing in the discarded ovary tissues to
perform the first successful in vitro fertilization procedure that resulted in pregnancy
and a birth in the world. Used only on animals before, it was the first successful
attempt of applying the technique to human, which was regarded revolutionary in
that time. For this success Dr. Cha was invited to speak at the annual American
Society of Fertility and Sterility forum in 1989, where he was given the honor of
the Best Paper Award. Back then, it was unheard of for a Korean scientist to give
an opening speech at a medical conference held in the U.S. Until today, Dr. Cha
is leading the world infertility and reproductive medicine field.
iCORD is the only Korean cord blood bank to provide a one-stop cord blood storage service, where patients can have the cord blood stored and transplanted for the treatments. iCORD works closely with CHA Bio & Diostech, a stem cell specialist company, to maintain the best infrastructure for related treatments. The media report that Dr. Cha has raised the level of professionalism and reliability in cord blood storage; and iCORD has been consistently ranked number one in consumer satisfaction indices, the studies conducted by many consumer organizations, in the categories of reliability, brand power, and service satisfaction.
|2004.||Best Paper Award, 60th Annual American Society of Reproductive Medicine ("ASRM") Conference|
|2003.||Plenary Prize, 59th Annual ASRM meeting|
|2000.||Best Pictorial Presentation Award, ASRM|
|1998.||Best Paper Award, the 16th Annual International Society of Fertility; the 54th ASRM Conference|
|1997.||Best Paper Award, Korea Foundation for the Advancement of Science & Creativity Best Paper Award, '97 European Society of Infertility Conference|
|1995.||Dr. Cha's paper makes the final for Best Paper Award at the 51th ASRM Conference.|
|1994.||Best Paper Award, the European Society of Reproductive Medicine. Final candidate, Best Paper Award, the 50th ASRM Conference.|
|1993.||Best Paper Award, annual Korean Society of Infertility forum.|
|1989.||Best Paper Award, ASRM.|